Kim SB et al. |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. |
2016 |
Int. J. Cancer |
pmid:27428671
|
Yu L et al. |
Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. |
2014 |
Int. J. Gynecol. Cancer |
pmid:24987913
|
Sauter A et al. |
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. |
2007 |
Int. J. Oncol. |
pmid:17332932
|
Zhang YG et al. |
Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. |
2016 |
Int. J. Syst. Evol. Microbiol. |
pmid:26486850
|
Shah MH et al. |
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. |
2016 |
Invest New Drugs |
pmid:26961907
|
Lapusan S et al. |
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. |
2012 |
Invest New Drugs |
pmid:21519855
|
Lieberman P and Castells M |
Desensitization to chemotherapeutic agents. |
2014 Jan-Feb |
J Allergy Clin Immunol Pract |
pmid:24565784
|
Rebert CS et al. |
Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. |
1984 |
J Appl Toxicol |
pmid:6542922
|
Sendur MA et al. |
Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? |
2013 Jul-Sep |
J BUON |
pmid:24065505
|
Wang C et al. |
Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. |
2016 |
J Chromatogr A |
pmid:27286648
|
Gupta M et al. |
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. |
2012 |
J Clin Pharmacol |
pmid:21953571
|
Zhong P et al. |
αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. |
2017 |
J Control Release |
pmid:27986551
|
Sibaud V et al. |
T-DM1 extravasation: first description. |
2016 |
J Eur Acad Dermatol Venereol |
pmid:25879278
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Parikh A et al. |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. |
2017 |
J Natl Compr Canc Netw |
pmid:28040715
|
Baron JM et al. |
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. |
2015 |
J Oncol Pharm Pract |
pmid:24682654
|
Shafaee MN et al. |
Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. |
2017 |
J Oncol Pract |
pmid:28678590
|
Mohamed HE et al. |
Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. |
2018 |
J Pharm Biomed Anal |
pmid:29258046
|
Liu Y et al. |
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). |
2017 |
J Pharm Biomed Anal |
pmid:28131055
|
Iwamoto N et al. |
LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. |
2017 |
J Pharm Biomed Anal |
pmid:28648785
|
Heudi O et al. |
Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. |
2016 |
J Pharm Biomed Anal |
pmid:26771131
|
Liu Z et al. |
An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. |
2004 |
J Pharm Biomed Anal |
pmid:15533675
|
Suchocki JA and Sneden AT |
Characterization of decomposition products of maytansine. |
1987 |
J Pharm Sci |
pmid:11002812
|
Wiggins B et al. |
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. |
2015 |
J Pharm Sci |
pmid:25631158
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Gibiansky L and Gibiansky E |
Target-mediated drug disposition model and its approximations for antibody-drug conjugates. |
2014 |
J Pharmacokinet Pharmacodyn |
pmid:24322877
|
Haddish-Berhane N et al. |
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. |
2013 |
J Pharmacokinet Pharmacodyn |
pmid:23933716
|
Jumbe NL et al. |
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. |
2010 |
J Pharmacokinet Pharmacodyn |
pmid:20424896
|
Yao Y et al. |
Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. |
2010 |
J Sep Sci |
pmid:20235129
|
Weiler D et al. |
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. |
2015 |
J Thorac Oncol |
pmid:25789838
|
Chuang JC et al. |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. |
2017 |
J Thorac Oncol |
pmid:28167203
|
Wang HH et al. |
Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. |
2010 |
J. Alzheimers Dis. |
pmid:20413892
|
Carroll BJ et al. |
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. |
2002 |
J. Am. Chem. Soc. |
pmid:11960423
|
Moss SJ et al. |
Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. |
2002 |
J. Am. Chem. Soc. |
pmid:12047169
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Spiteller P et al. |
The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. |
2003 |
J. Am. Chem. Soc. |
pmid:14624546
|
Wenzel SC et al. |
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. |
2006 |
J. Am. Chem. Soc. |
pmid:17076505
|
Hatano K et al. |
Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. |
1982 |
J. Antibiot. |
pmid:7174527
|
Tanida S et al. |
Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. |
1981 |
J. Antibiot. |
pmid:7275830
|
Izawa M et al. |
Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. |
1981 |
J. Antibiot. |
pmid:7275831
|
Tanida S et al. |
Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. |
1980 |
J. Antibiot. |
pmid:7380728
|
Nakahama K et al. |
Microbial conversion of ansamitocin. |
1981 |
J. Antibiot. |
pmid:7333971
|
Izawa M et al. |
Demethylation of ansamitocins and related compounds. |
1981 |
J. Antibiot. |
pmid:7333972
|
Izawa M et al. |
Hydroxylation of ansamitocin P-3. |
1981 |
J. Antibiot. |
pmid:7333973
|
Lu C et al. |
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. |
2004 |
J. Antibiot. |
pmid:15303496
|
Lin CM and Hamel E |
Effects of inhibitors of tubulin polymerization on GTP hydrolysis. |
1981 |
J. Biol. Chem. |
pmid:6114958
|
Roach MC and Ludueña RF |
Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. |
1984 |
J. Biol. Chem. |
pmid:6480599
|
Bai RL et al. |
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. |
1990 |
J. Biol. Chem. |
pmid:2211617
|
Bai RL et al. |
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. |
1991 |
J. Biol. Chem. |
pmid:1874739
|